S-Adenosylhomocysteine - A better indicator of vascular disease than homocysteine?

American Journal of Clinical Nutrition

Volumn 86, Issue 6, 2007, Pages 1581-1585

  Wagner, Conrad ^a,b   Koury, Mark J ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Homocysteine; Methionine; Plasma; Risk factors; S adenosylhomocysteine; S adenosylmethionine; Vascular disease

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BETAINE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; MECOBALAMIN; METHIONINE; METHIONINE SYNTHASE; METHYLTRANSFERASE; PYRIDOXINE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE;

ALZHEIMER DISEASE; CEREBROVASCULAR DISEASE; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNOASSAY; ISCHEMIC HEART DISEASE; LOADING TEST; METHYLATION; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK ASSESSMENT; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION;

EID: 36849067359     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/86.5.1581     Document Type: Review

References (53)

1. Cantoni GL, Chiang PK. The role of S-adenosylhomocysteine hydrolase in the control of biological methylations. In: Cavallini D, Gaull GE, Zappia V, eds. Natural sulfur compounds: novel biochemical and structural aspects. New York, NY: Plenum Press, 1980:67-80.
2. Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Haemost 2000;26:219-25.
3. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
4. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976;57:1079-82.
5. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
6. Brattstrom LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia - a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 1984;15:1012-6.
7. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
8. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
9. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9.
10. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202-8.
11. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473-501.
12. Selhub J, Jacques PF, Bostom AG, et al. Relationship between plasma homocysteine, vitamin status and extracranial carotid-artery stenosis in the Framingham Study population. J Nutr 1996;126(suppl):1258S-65S.
13. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-54.
14. Heinecke JW. Unique aspects of sulfur chemistry: homocysteine and lipid oxidation. In: Carmel R, Jacobsen DW, eds. Homocysteine in health and disease. Cambridge, United Kingdom: Cambridge University Press, 2001:32-8.
15. Ling Q, Hajjar KA. Inhibition of endothelial cell thromboresistance by homocysteine. J Nutr 2000;130(suppl):373S-6S.
16. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.
17. Gow AJ, Cobb F, Stamler JS. Homocysteine, nitric oxide and nitrosothiols. In: Carmel R, Jacobsen DW, eds. Homocysteine in health and disease. Cambridge, United Kingdom: Cambridge University Press, 2001:39-45.
18. Wang H, Yoshizumi M, Lai K, et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997;272:25380-5.
19. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994;91:6369-73.
20. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 1997;272:1935-42.
21. Hossain GS, Van Thienen JV, Werstuck GH, et al. TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the development of atherosclerosis in hyperhomocysteinemia. J Biol Chem 2003;278:30317-27.
22. Jacobsen DW. Practical chemistry of homocysteine and other thios. In: Carmel R, Jacobsen DW, eds. Homocysteine in health and disease. Cambridge, United Kingdom: Cambridge University Press, 2001:9-20.
23. Clarke S, Banfield K. S-adenosylmethionine-dependent methyltransferases. In: Carmel R, Jacobsen DW, eds. Homocysteine in health and disease. Cambridge, United Kingdm: Cambridge University Press, 2001:63-78.
24. Cantoni GL, Richards HH, Chiang PK. Inhibitors of S-adenosylhomocysteine hydrolase and their role in the regulation of biological methylation. In: Usdin E, Borchardt RT, Creveling CR, eds. Transmethylation. New York, NY: Elsevier North Holland, 1978:155-64.
25. Hershfield MS, Kredich NM, Koller CA, et al. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2′-deoxycoformycin alone and in combination with 9-beta-D- arabinofuranosyladenine. Cancer Res 1983;43:3451-8.
26. Caudill MA, Wang JC, Melnyk S, et al. Intracellular S-adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyl-deficient cystathionine beta-synthase heterozygous mice. J Nutr 2001;131:2811-8.
27. Capdevila A, Decha-Umphai W, Song KH, Borchardt RT, Wagner C. Pancreatic exocrine secretion is blocked by inhibitors of methylation. Arch Biochem Biophys 1997;345:47-55.
28. Melnyk S, Pogribna M, Pogribny IP, Yi P, James SJ. Measurement of plasma and intracellular S-adenosylmethionine and S-adenosylhomocysteine utilizing coulometric electrochemical detection: alterations with plasma homocysteine and pyridoxal 5′-phosphate concentrations. Clin Chem 2000 46:265-72.
29. Struys EA, Jansen EE, de Meer K, Jakobs C. Determination of S-adenosylmethionine and S-adenosylhomocysteine in plasma and cerebrospinal fluid by stable-isotope dilution tandem mass spectrometry. Clin Chem 2000;46:1650-6.
30. Loehrer FM, Angst CP, Brunner FP, Haefeli WE, Fowler B. Evidence for disturbed S-adenosylmethionine:S-adenosylhomocysteine ratio in patients with end-stage renal failure: a cause for disturbed methylation reactions? Nephrol Dial Transplant 1998;13:656-61.
31. Kerins DM, Koury MJ, Capdevila A, Rana S, Wagner C. Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am J Clin Nutr 2001;74:723-9.
32. House JD, Brosnan ME, Brosnan JT. Characterization of homocysteine metabolism in the rat kidney. Biochem J 1997;328:287-92.
33. van Guldener C, Robinson K. Homocysteine and renal disease. Semin Thromb Hemost 2000;26:313-24.
34. De Vriese AS, Verbeke F, Schrijvers BF, Lameire NH. Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure? Kidney Int 2002;61:1199-209.
35. Wagner C, Stone WJ, Koury MJ, Dupont WD, Kerins DM. S-adenosylhomocysteine is a more sensitive indicator of renal insufficiency than homocysteine. Nutr Res 2004;24:487-94.
36. Jabs K, Koury MJ, Dupont WD, Wagner C. Relationship between plasma S-adenosylhomocysteine concentration and glomerular filtration rate in children. Metabolism 2006;55:252-7.
37. Stabler SP, Allen RH. Quantification of serum and urinary S-adenosylmethionine and S-adenosylhomocysteine by stable-isotope-dilution liquid chromatography-mass spectrometry. Clin Chem 2004;50:365-72.
38. van Guldener C, Donker AJ, Jakobs C, Teerlink T, de Meer K, Stehouwer CD. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998;54:166-9.
39. Ueland P, Refsum H, Brattstrom L. Plasma Homocysteine and cardiovascular disease. In: Francis RB, ed. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York, NY: Marcel Dekker Inc, 1992:183-235.
40. Becker A, Smulders YM, Teerlink T, et al. S-adenosylhomocysteine and the ratio of S-adenosylmethionine to S-adenosylhomocysteine are not related to folate, cobalamin and vitamin B6 concentrations. Eur J Clin Invest 2003;33:17-25.
41. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
42. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
43. Clarke R, Lewington S, Sherliker P, Armitage J. Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia. Curr Opin Clin Nutr Metab Care 2007;10:32-9.
44. Frantzen F, Faaren AL, Alfheim I, Nordhei AK. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998;44:311-6.
45. Loehrer FM, Haefeli WE, Angst CP, Browne G, Frick G, Fowler B. Effect of methionine loading on 5-methyltetrahydrofolate, S-adenosylmethionine and S-adenosylhomocysteine in plasma of healthy humans. Clin Sci 1996;91:79-86.
46. Castro R, Rivera I, Struys EA, et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem 2003;49:1292-6.
47. Capdevila A, Wagner C. Measurement of plasma S-adenosylmethionine and S-adenosylhomocysteine as their fluorescent isoindoles. Anal Biochem 1998;264:180-4.
48. Gellekink H, van Oppenraaij-Emmerzaal D, van Rooij A, Struys EA, den Heijer M, Blom HJ. Stable-isotope dilution liquid chromatography-electrospray injection tandem mass spectrometry method for fast, selective measurement of S-adenosylmethionine and S-adenosylhomocysteine in plasma. Clin Chem 2005;51:1487-92.
49. Capdevila A, Burk RF, Freedman J, Wagner C. A simple rapid immunoassay for S-adenosylhomocysteine in plasma. J Nutr Biochem 2007 May 15 (Epub ahead of print).
50. Bottiglieri T, Hyland K. S-adenosylmethionine levels in psychiatric and neurological disorders: a review. Acta Neurol Scand. Suppl 1994;154:19-26.
51. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-83.
52. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002;33:2351-6.
53. Obeid R, Kostopoulos P, Knapp JP, et al. Biomarkers of folate and vitamin B12 are related in blood and cerebrospinal fluid. Clin Chem 2007;53:326-33.